Geoffrey Oxnard Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

1/2020

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Geoffrey Oxnard Research Topics

Disease

3	Neoplasms (Cancer) 01/2023 - 08/2015
2	Lung Neoplasms (Lung Cancer) 01/2020 - 08/2015
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2023
1	Breast Neoplasms (Breast Cancer) 01/2023
1	Adenocarcinoma 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020
1	Disease Progression 01/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2020
1	Adenocarcinoma of Lung 08/2015

Drug/Important Bio-Agent (IBA)

1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023
1	Circulating Tumor DNAIBA 01/2023
1	ErbB Receptors (EGF Receptor)IBA 01/2023
1	atezolizumabIBA 01/2023
1	Trastuzumab (Herceptin)FDA Link 01/2022
1	human ERBB2 proteinIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 01/2020
1	osimertinibIBA 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	Cytokine Receptors (Cytokine Receptor)IBA 08/2015
1	Amino Acids FDA Link 08/2015
1	Immune Checkpoint InhibitorsIBA 08/2015

Therapy/Procedure

2	Therapeutics 01/2022 - 08/2015